|
|
|
|
|
High Throughput Screening (HTS) |
|
|
|
HD Biosciences offers high-quality, and cost-effective screening services that cover from biochemical, radiometric, cell-based, to high content, multiplex, LC/MS based screening for the hit identification and lead discovery. Our State of the Art screening center is capable of |
producing over 100,000 data points per day, per individual primary screening. |
|
For years, HD Biosciences has an excellent track record in HTS services. We are the designated “The Center of the Excellence in Hit Identification and Lead Discovery” for several global pharmaceutical companies and support their company-wide needs in |
screening activities. |
|
In addition to high throughput screening services, HD Biosciences also offer the compound management supports for the partners/clients. The company currently handles the size of over 3 million compounds in single and/or compressed formats, both dry and DMSO, for several clients to support daily screening activities, as well as global compound distribution. Besides client’s compounds for screening activities, HD Biosciences proprietary diversified TCM-based natural product library with over 10,000 HPLC- |
fractionated samples, is also available for custom screening services. |
|
|
|
Integrated Screening Platform |
|
Compound Management |
• |
|
Designated & secured storage for individual HTS/SAR project for each client |
• |
SOP enforced process to support compound receiving, registration and storage with 2D |
|
barcode option |
• |
Experience of handling over 3 million compounds under varieties of formats for multiple |
|
clients (RAMP plates, dry, DMSO) |
• |
Proprietary compound data management system (CPMS) to provide solutions for t |
|
information tracking from vials/plates, assay/screening, to data processing/output and |
managemen |
|
Assay Development/Transfer & Screening |
• |
|
Designated POC for individual program on assay development, optimization and |
|
validation |
• |
Expertise in assay adaptation to HTS for seamless assay-HTS transfer and operation |
• |
On site, real time checking for screening QA/QC |
• |
Varieties of assay and screen formats to address unmet needs |
|
Data Management & IT Support |
• |
|
CPMS and other database tools to capture precise information flow |
• |
Strong IT Infrastructure with variety of data analysis tools to facilitate data recording, |
|
curve fitting, visualization and reporting |
• |
VPN and e-notebook available for secured data sharing and transfer |
• |
Designated POC for secured data review and assurance of data integrity |
|
Project Management & Quality Assurance Support |
• |
|
Project Management & Quality Assurance Support |
• |
Final data quality assurance with notebook archiving and compliance |
• |
Close communication with clients for transparent operation & progress update |
|
|
HTS and SAR Screening Workflow |
 |
|
Quality Control and Assurance |
|
Equipment Regular QC & Calibration |
|
• |
|
All equipment were professionally calibrated regularly and before |
|
each campaign |
|
|
Data QC - NIH Guidance & Beyond |
• |
|
Cross-day, cross-plate tests of SW, EC/IC50 & the rank order of |
|
potencies of reference compounds with acceptable variations |
• |
ZPE, HPE, MSR and Z’ factor tests in three separate experiments |
|
in assay validation phase |
• |
Reference compounds with multiple concentrations imbedding in |
|
individual screening campaign |
• |
Z factor summary for every primary screening |
|
|
|
• |
|
Compound QC for HTS selected hits to eliminate mismatched |
|
biological and chemical data |
• |
Data analysis result reported within 24h after screening result |
• |
UPLC/MS based analysis with a throughput > 3,000 compounds |
|
per week |
|
|
|
|
|
|
Primary HTS, Hit Confirmation and Hit Follow-up |
|
 |
|
• |
|
470,000+ compounds library screened on a Amplex red/HRP based fluorescence assay |
|
on Envision |
• |
Hit rate: 2.1% (threshold: 30% inhibition) |
• |
Hit confirmation rate: 75.58% |
• |
Plate failure rate: < 3% |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
---------------------- |
|
|
---------------------- |
|
|
|
|
|
|
|
|
|
|
|
|
|